Physician profile
Arjun Banerjee
NPI 1629021183
$3,015.21
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,656 · 2020: $87.91 · 2021: $654 · 2022: $456 · 2023: $54.46 · 2024: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $161.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,052.22 | 2019-2022 | |
| Lilly USA, LLC | $187.83 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $132.26 | 2019 | |
| Amgen INC. | $120.63 | 2019 | |
| Allergan, INC. | $119.93 | 2019 | |
| Pfizer INC. | $107.95 | 2019 | |
| Inspire Medical Systems, INC. | $106.95 | 2024 | Inspire |
| Medtronic Vascular, INC. | $87.91 | 2020 | |
| Corcept Therapeutics | $86.75 | 2021 | |
| Merck Sharp & Dohme LLC | $84.08 | 2019 | |
| Glaxosmithkline, LLC. | $76.52 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.46 | 2019 | |
| Radius Health, INC. | $65.06 | 2019-2023 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.84 | 2019 | |
| Novartis Pharmaceuticals Corporation | $60.08 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $57.80 | 2019 | |
| Neurocrine Biosciences, INC. | $52.57 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $49.63 | 2019 | |
| Amarin Pharma, INC. | $49.08 | 2019 | |
| Celgene Corporation | $45.79 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $43.60 | 2019 | |
| Scilex Pharmaceuticals INC. | $40.23 | 2019 | |
| Mdd US Operations, LLC | $39.43 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $30.64 | 2019 | |
| Janssen Pharmaceuticals, INC | $30.58 | 2019 | |
| Abbvie INC. | $27.71 | 2019 | |
| Astellas Pharma US INC | $27.06 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.70 | 2019 | |
| Aytu Biopharma, INC. | $15.58 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.61 | 2019 | |
| Mylan Specialty L.P. | $14.46 | 2019 | |
| Metuchen Pharmaceuticals | $11.77 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.28 | 2019 | |
| Pacira Therapeutics, INC. | $11.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arjun Banerjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.